| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $155,961 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Hitchcock Michael J.M. | director | 1 | $100,600 | 0 | $0 | $100,600 |
| Valle Franco | Chief Financial Officer | 1 | $55,361 | 0 | $0 | $55,361 |
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Over the last 12 months, insiders at Biomea Fusion, Inc. have bought $155,961 and sold $0 worth of Biomea Fusion, Inc. stock.
On average, over the past 5 years, insiders at Biomea Fusion, Inc. have bought $8.28M and sold $13.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hitchcock Michael J.M. (director) — $100,600. Valle Franco (Chief Financial Officer) — $55,361.
The last purchase of 10,000 shares for transaction amount of $100,600 was made by Hitchcock Michael J.M. (director) on 2024‑09‑30.
| 2024-09-30 | Hitchcock Michael J.M. | director | 10,000 0.029% | $10.06 | $100,600 | -60.59% | ||
| 2024-06-11 | Valle Franco | Chief Financial Officer | 12,509 0.0348% | $4.43 | $55,361 | +11.96% | ||
| 2023-06-01 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 50,000 0.1638% | $34.56 | $1.73M | -57.49% | |
| 2023-05-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 75,000 0.2524% | $33.81 | $2.54M | -55.29% | |
| 2023-05-12 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 25,000 0.0841% | $33.84 | $846,000 | -53.59% | |
| 2023-05-09 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 150,000 0.5185% | $34.50 | $5.18M | -53.05% | |
| 2023-05-08 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 100,000 0.3445% | $33.99 | $3.4M | -52.35% | |
| 2023-04-20 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6723% | $29.12 | $5.82M | -43.68% | |
| 2023-03-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6812% | $31.25 | $6.25M | -45.45% | |
| 2023-03-30 | Chen Bihua | 400,000 1.2695% | $30.00 | $12M | -47.02% | |||
| 2022-11-14 | Hitchcock Michael J.M. | director | 5,000 0.0169% | $7.93 | $39,650 | +88.58% | ||
| 2022-11-11 | Valle Franco | Chief Financial Officer | 4,100 0.0134% | $7.63 | $31,286 | +90.83% | ||
| 2022-08-16 | A2A Pharmaceuticals, Inc. | 30,684 0.1067% | $13.87 | $425,648 | -9.55% | |||
| 2022-07-21 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1118% | $11.21 | $388,516 | -2.11% | ||
| 2022-06-24 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1168% | $11.76 | $407,578 | -5.69% | ||
| 2022-01-14 | Valle Franco | Chief Financial Officer | 10,000 0.033% | $8.68 | $86,767 | -17.39% | ||
| 2021-09-17 | Stergiopoulos Sotirios | director | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | ||
| 2021-09-17 | A2A Pharmaceuticals, Inc. | 10 percent owner | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | ||
| 2021-08-23 | Erdtmann Rainer M | President & COO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% | ||
| 2021-08-23 | Butler Thomas Andrew | CEO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% |
| Valle Franco | Chief Financial Officer | 42500 0.1131% | $66,725.00 | 3 | 0 | +36.72% |
| Hitchcock Michael J.M. | director | 15000 0.0399% | $23,550.00 | 2 | 0 | +88.58% |
| Stergiopoulos Sotirios | director | 4400000 11.7108% | $6.91M | 1 | 0 | <0.0001% |
| Chen Bihua | 3570872 9.504% | $5.61M | 2 | 0 | <0.0001% | |
| A2A Pharmaceuticals, Inc. | 10 percent owner | 3500000 9.3154% | $5.5M | 2 | 9 | <0.0001% |
| Erdtmann Rainer M | President & COO | 228470 0.6081% | $358,697.90 | 4 | 0 | <0.0001% |
| Butler Thomas Andrew | CEO | 228470 0.6081% | $358,697.90 | 4 | 0 | <0.0001% |
$4,613,182 | 103 | -36.00% | $55.16M | |
$81,638,324 | 48 | 7.58% | $59.48M | |
$18,752,549 | 33 | -28.39% | $56.5M | |
$241,165 | 22 | -16.72% | $57.09M | |
$1,087,418 | 21 | 1.95% | $58.82M | |
$160,539,875 | 21 | -6.57% | $58.76M | |
$167,476,357 | 20 | -1.54% | $55.44M | |
Biomea Fusion, Inc. (BMEA) | $32,972,199 | 16 | -10.77% | $58.99M |
$245,302 | 15 | -4.08% | $60.89M | |
$28,281,140 | 14 | 18.42% | $61.66M | |
$18,535,159 | 14 | 57.32% | $57.07M | |
$32,684,649 | 8 | -15.84% | $61.98M | |
$4,895,542 | 8 | -11.85% | $64.44M | |
$99,355,998 | 7 | -65.74% | $64.21M | |
$8,470,804 | 6 | -13.28% | $55.8M | |
$4,745,999 | 5 | -4.91% | $66.21M | |
$195,184 | 5 | 6.34% | $56.46M | |
$762,555 | 4 | -34.52% | $62.69M | |
$4,030 | 1 | 9.14% | $62.35M |
| Increased Positions | 44 | +35.48% | 2M | +7.28% |
| Decreased Positions | 50 | -40.32% | 3M | -14.66% |
| New Positions | 12 | New | 265,686 | New |
| Sold Out Positions | 22 | Sold Out | 2M | Sold Out |
| Total Postitions | 118 | -4.84% | 21M | -7.37% |
| Fmr Llc | $11,850.00 | 14.31% | 5.44M | +4,278 | +0.08% | 2024-12-31 |
| Cormorant Asset Management, Lp | $7,785.00 | 9.4% | 3.57M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $4,709.00 | 5.68% | 2.16M | -59,305 | -2.67% | 2025-03-31 |
| Baker Bros. Advisors Lp | $3,165.00 | 3.82% | 1.45M | -656,959 | -31.15% | 2024-12-31 |
| Vanguard Group Inc | $3,054.00 | 3.69% | 1.4M | +3,216 | +0.23% | 2024-12-31 |
| Aisling Capital Management Lp | $1,741.00 | 2.1% | 798,757 | 0 | 0% | 2024-12-31 |
| State Street Corp | $1,318.00 | 1.59% | 604,364 | -36,831 | -5.74% | 2024-12-31 |
| Geode Capital Management, Llc | $1,317.00 | 1.59% | 604,147 | +2,668 | +0.44% | 2024-12-31 |
| Two Sigma Investments, Lp | $1,221.00 | 1.47% | 559,930 | +286,049 | +104.44% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $1,090.00 | 1.32% | 500,000 | -400,000 | -44.44% | 2024-12-31 |